Antiplatelet testing in neurointervention: we cannot ignore the signs.

about

Platelet function testing: does a randomized controlled trial settle the debate?

P2860

Q48154693-FD087E6C-02EA-43C6-A92E-F5193CE3A454

P2860

Antiplatelet testing in neurointervention: we cannot ignore the signs.

Item

http://www.wikidata.org/entity/Q38114045

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Antiplatelet testing in neurointervention: we cannot ignore the signs.

@en

type

Item

label

Antiplatelet testing in neurointervention: we cannot ignore the signs.

@en

prefLabel

Antiplatelet testing in neurointervention: we cannot ignore the signs.

@en

P1476

Antiplatelet testing in neurointervention: we cannot ignore the signs.

@en

P2093

Thabele M Leslie-Mazwi

http://www.w3.org/2001/XMLSchema#string

P2860

Aspirin resistance

Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures.

Mechanisms of stroke after intracranial angioplasty and stenting in the SAMMPRIS trial.

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Associ

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.

Clopidogrel hyper-response and bleeding risk in neurointerventional procedures.

P304

277-279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/NEURINTSURG-2013-010809

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23761594

http://www.w3.org/2001/XMLSchema#string

Antiplatelet testing in neurointervention: we cannot ignore the signs.

about

P2860

P2860

Antiplatelet testing in neurointervention: we cannot ignore the signs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698